Loading…
Reported covered position: New Jersey Caucus Staffer 2006-2008
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Medicare Decisions Accountability Act of 2011
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Supporting the repeal of the Independent Payment Advisory Board (IPAB); specifically S 668 and HR 452.
Responsible Child Tax Credit Eligibility Verification Act of 2012
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting research and development tax credits, including HR 942, S 4018 and HR 6165.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2011 · second_quarter · Q2
Supporting the repeal of the Independent Payment Advisory Board (IPAB); specifically S 668 and HR 452.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2011 · second_quarter · Q2
Source: Senate LDA
American Research and Competitiveness Act of 2011
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting research and development tax credits, including HR 942, S 4018 and HR 6165.
Life Sciences Jobs and Investment Act of 2010
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting research and development tax credits, including HR 942, S 4018 and HR 6165.
Pathway for Biosimilars Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
promoting awareness of the research-based biopharmaceutical and medical technology sector Eshoo-Barton Pathways to Biosimilars Act HR 1548 Kennedy Pathways to Biosimilars Act America's Affordable Health Choices Act HR.3200 America's Healthy Future Act HR 2502 Comparative Effectiveness Research Act of 2009
Comparative Effectiveness Research Act of 2009
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
promoting awareness of the research-based biopharmaceutical and medical technology sector Eshoo-Barton Pathways to Biosimilars Act HR 1548 Kennedy Pathways to Biosimilars Act America's Affordable Health Choices Act HR.3200 America's Healthy Future Act HR 2502 Comparative Effectiveness Research Act of 2009
America's Affordable Health Choices Act of 2009
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
promoting awareness of the research-based biopharmaceutical and medical technology sector Eshoo-Barton Pathways to Biosimilars Act HR 1548 Kennedy Pathways to Biosimilars Act America's Affordable Health Choices Act HR.3200 America's Healthy Future Act HR 2502 Comparative Effectiveness Research Act of 2009
Life Sciences Jobs and Investment Act of 2010
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
HR 6165 Life Sciences Investment Act
Patent Reform Act of 2009
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
S. 515 The Patent Reform Act of 2009
Patent Reform Act of 2009
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
S.515 The Patent Reform Act of 2009
Patent Reform Act of 2009
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
S.515 The Patent Reform Act of 2009
Patent Reform Act of 2009
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
S. 515 The Patent Reform Act of 2009
Pathway for Biosimilars Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
promoting awareness and advocacy of the biopharmaceutical and medical technology industry in New Jersey Eshoo-Barton Pathways to Biosimilars Act HR 1548 Kennedy Pathways to Biosimilars Act Chronic disease prevention and treatment incentives in health care reform America's Affordable Health Choices Act HR.3200 America's Healthy Future Act HR 2502 Comparative Effectiveness Research Act of 2009
Pathway for Biosimilars Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
promoting awareness and advocacy of the biopharmaceutical and medical technology industry in New Jersey Eshoo-Barton Pathways to Biosimilars Act HR 1548 Kennedy Pathways to Biosimilars Act Chronic disease prevention and treatment incentives in health care reform America's Affordable Health Choices Act HR.3200 America's Healthy Future Act
Pathway for Biosimilars Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
promoting awareness and advocacy of the biopharmaceutical and medical technology industry in New Jersey Support Eshoo-Barton Pathways to Biosimilars Act HR 1548 Support Kennedy Pathways to Biosimilars Act Chronic disease prevention and treatment incentives in health care reform health care reform- supported open access and choice of plans
Comparative Effectiveness Research Act of 2009
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
promoting awareness and advocacy of the biopharmaceutical and medical technology industry in New Jersey Eshoo-Barton Pathways to Biosimilars Act HR 1548 Kennedy Pathways to Biosimilars Act Chronic disease prevention and treatment incentives in health care reform America's Affordable Health Choices Act HR.3200 America's Healthy Future Act HR 2502 Comparative Effectiveness Research Act of 2009
America's Affordable Health Choices Act of 2009
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
promoting awareness and advocacy of the biopharmaceutical and medical technology industry in New Jersey Eshoo-Barton Pathways to Biosimilars Act HR 1548 Kennedy Pathways to Biosimilars Act Chronic disease prevention and treatment incentives in health care reform America's Affordable Health Choices Act HR.3200 America's Healthy Future Act HR 2502 Comparative Effectiveness Research Act of 2009
America's Affordable Health Choices Act of 2009
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
promoting awareness and advocacy of the biopharmaceutical and medical technology industry in New Jersey Eshoo-Barton Pathways to Biosimilars Act HR 1548 Kennedy Pathways to Biosimilars Act Chronic disease prevention and treatment incentives in health care reform America's Affordable Health Choices Act HR.3200 America's Healthy Future Act
To amend title 5, United States Code, to increase the level of Government contributions under the Federal employees health benefits program.
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Supporting legislation to regulate tobacco products through the FDA-opposing amendments to important prescription drugs HR 1256
Supporting reform of the patent system to make it more efficient, equitable and timely; specifically, S23 and HR1249.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2011 · first_quarter · Q1
Promoting an updated, more efficient patent reform system, specifically S. 23 and HR 1249.
Promoting the prevention of health care-associated infections through value-based purchasing programs in CMS.
Promoting research and development tax credits, including HR 942, S 4018 and HR 6165.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2010 · fourth_quarter · Q4
S. 515 The Patent Reform Act of 2009
HR 6165 Life Sciences Investment Act
Promoting awareness of the biopharmaceutical and medical technology sectors.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2010 · third_quarter · Q3
promoting awareness of the biopharmaceutical and medical technology sectors promoting awareness of medical devices and their regulatory pathway through the FDA Promoting the prevention of health care associated infections through value based purchasing programs in CMS.
S.515 The Patent Reform Act of 2009
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2010 · second_quarter · Q2
promoting awareness of the biopharmaceutical and medical technology sectors promoting awareness of medical devices and their regulatory pathway through the FDA Promoting the prevention of health care associated infections through value based purchasing programs in CMS.
S.515 The Patent Reform Act of 2009
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2010 · first_quarter · Q1
promoting awareness of the research-based biopharmaceutical and medical technology sector Eshoo-Barton Pathways to Biosimilars Act HR 1548 Kennedy Pathways to Biosimilars Act America's Affordable Health Choices Act HR.3200 America's Healthy Future Act HR 2502 Comparative Effectiveness Research Act of 2009
S. 515 The Patent Reform Act of 2009
Advocating on behalf of Medicare Part D open access and encouraging open market access to medications
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2009 · fourth_quarter · Q4
promoting awareness and advocacy of the biopharmaceutical and medical technology industry in New Jersey Eshoo-Barton Pathways to Biosimilars Act HR 1548 Kennedy Pathways to Biosimilars Act Chronic disease prevention and treatment incentives in health care reform America's Affordable Health Choices Act HR.3200 America's Healthy Future Act HR 2502 Comparative Effectiveness Research Act of 2009
Advocating on behalf of Medicare Part D open access and encouraging open market access to medications
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2009 · third_quarter · Q3
promoting awareness and advocacy of the biopharmaceutical and medical technology industry in New Jersey Eshoo-Barton Pathways to Biosimilars Act HR 1548 Kennedy Pathways to Biosimilars Act Chronic disease prevention and treatment incentives in health care reform America's Affordable Health Choices Act HR.3200 America's Healthy Future Act
Advocating on behalf of Medicare Part D open access and encouraging open market access to medications
Medical Device Safety Act of 2009
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2009 · second_quarter · Q2
promoting awareness and advocacy of the biopharmaceutical and medical technology industry in New Jersey Support Eshoo-Barton Pathways to Biosimilars Act HR 1548 Support Kennedy Pathways to Biosimilars Act Chronic disease prevention and treatment incentives in health care reform health care reform- supported open access and choice of plans
Supporting legislation to regulate tobacco products through the FDA-opposing amendments to important prescription drugs HR 1256
Amending the Patent Reform Act of 2009
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2009 · first_quarter · Q1
Oppose Medical Device Safety Act of 2009
Amending the Patent Reform Act of 2009
Advocating on behalf of Medicare Part D open access and encouraging open market access to medications
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2008 · fourth_quarter · RA
importation in appropriations bills, patent reform, health care reform, pharmaceutcial and medical device pricing, reimbursement issues, Medicare Part D coverage and pricing, corporate tax, trade agreeements, preemption.
importation in appropriations bills, patent reform, health care reform, pharmaceutcial and medical device pricing, reimbursement issues, Medicare Part D coverage and pricing, corporate tax, trade agreeements, preemption.
importation in appropriations bills, patent reform, health care reform, pharmaceutcial and medical device pricing, reimbursement issues, Medicare Part D coverage and pricing, corporate tax, trade agreeements, preemption.
Medical Device Safety Act of 2009
Advocating on behalf of Medicare Part D open access and encouraging open market access to medications
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Support Eshoo/Barton Pathways to Biosimilars Act Support Kennedy Pathways to Biosimilars Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
importation in appropriations bills, patent reform, health care reform, pharmaceutcial and medical device pricing, reimbursement issues, Medicare Part D coverage and pricing, corporate tax, trade agreeements, preemption.
importation in appropriations bills, patent reform, health care reform, pharmaceutcial and medical device pricing, reimbursement issues, Medicare Part D coverage and pricing, corporate tax, trade agreeements, preemption.
importation in appropriations bills, patent reform, health care reform, pharmaceutcial and medical device pricing, reimbursement issues, Medicare Part D coverage and pricing, corporate tax, trade agreeements, preemption.
importation in appropriations bills, patent reform, health care reform, pharmaceutcial and medical device pricing, reimbursement issues, Medicare Part D coverage and pricing, corporate tax, trade agreeements, preemption.
importation in appropriations bills, patent reform, health care reform, pharmaceutcial and medical device pricing, reimbursement issues, Medicare Part D coverage and pricing, corporate tax, trade agreeements, preemption.